关键词: 前列腺肿瘤, 醋酸阿比特龙, 转移性前列腺癌, 激素敏感性前列腺癌, 去势抵抗性前列腺癌, 治疗结果

Abstract: Abiraterone acetate（AA），a new antiandrogen，has just recently been introduced into the Chinese market，and used once for most patients. We retrospectively analyzed the diagnosis and treatment process of two cases of metastatic prostate cancer（mPC）treated using a comprehensive treatment scheme including the “sandwich” therapy with AA，and found this scheme may be effective for mPC. Moreover，we also found that the response time of the first AA treatment may be longer if the first AA treatment was stopped as early as possible at the end of the hormone-sensitive period，but that may be shorter if being stopped later in the castrate-resistant period. Furthermore，early discontinuation of the first AA treatment significantly prolonged the overall drug response period and the cancer-specific survival. Therefore，the "sandwich" regimen of AA could be used as a new strategy to improve the efficacy of mPC. And the earlier discontinuation regimen will be more conducive to optimizing the existing sequential treatment of mPC than the later discontinuation regimen.

Key words: Prostatic neoplasms , Abiraterone acetate, Metastatic prostate cancer, Hormone sensitive prostate cancer, Castrate-resistant prostate cancer, Treatment outcome